CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2011-01-06): No benefit from adjuvant bevacizumab for colon cancer metastases to liver

Drug & Device Development

No benefit from adjuvant bevacizumab for colon cancer metastases to liver

Last Updated: 2011-01-06 19:34:22 -0400 (Reuters Health)

NEW YORK (Reuters Health) - The addition of bevacizumab to hepatic arterial infusion and systemic chemotherapy does not improve survival in patients who have undergone liver resection for metastases from colorectal cancer.

These findings, from a small phase II trial by researchers at Memorial Sloan-Kettering Cancer Center, New York, were published online on December 28 by the Journal of Clinical Oncology.

"The study cannot provide definitive results because of its size," write Dr. Nancy E. Kemeny and colleagues, but it does suggest that in addition to not lengthening patients' survival, bevacizumab increased biliary toxicity.

Four-year survival following liver resection was 81% in the bevacizumab arm and 85% in the control arm.

The authors note that when the current trial began, no trials using adjuvant bevacizumab to treat colon cancer had been published. Bevacizumab is an antivascular endothelial growth factor A monoclonal antibody first approved in 2004.

Since then, however, a trial of systemic fluorouracil, leucovorin and oxaliplatin with or without bevacizumab in patients with stage II or III colon cancer found no difference in disease-free survival.

Similarly, another trial found no disease-free survival benefit from bevacizumab added to chemotherapy in patients with stage III colon cancer.

The current study involved 73 patients who had colorectal adenocarcinoma with fully resected liver metastases.

Chemotherapy began four to five weeks after surgery. Adjuvant hepatic arterial infusion with fluorodeoxyuridine and dexamethasone took place on day one of a five-week cycle.

On days 15 and 29, patients who had not previously been given oxaliplatin received it (85 mg/m2), along with leucovorin (400 mg/m2), followed by a 48-hour infusion of fluorouracil (2,000 mg/m2). Those who had previously received oxaliplatin were instead given irinotecan (150 mg/m2) with the same doses of leucovorin and fluorouracil.

Participants in the bevacizumab arm received that drug (5 mg/kg) also on days 15 and 29.

The majority of patients in each arm received all six planned cycles of chemotherapy.

The study was terminated early because of signs of biliary toxicity in the bevacizumab arm. Bilirubin levels more than 3 mg/dl and biliary stents were significantly more common among patients in the bevacizumab arm.

The study was supported in part by Genentech, which makes bevacizumab under the trade name Avastin.

SOURCE: http://bit.ly/fPCN3b

J Clin Oncol 2010.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.